5: Changes in TNFR1 ratios in the first week post-myeloablative allogeneic BMT correlate with GVHD, TRM and OS in children  by Kitko, C. et al.
CIBMTR Best Abstract Awards for Clinical Research
Each year the Center for International Blood and Marrow Transplant Research presents Best Abstract Awards to
recognize outstanding clinical research. The abstracts receiving the award are those that were scored highest by the
Abstract Review Committees. Each award is accompanied by a prize of $1,000. The awards are supported by an
unrestricted educational grant from Gambro BCT.
4
EFFECTS OF MINOR HISTOCOMPATIBILITY ANTIGEN MISMATCHING
ON CLINICAL OUTCOME IN HLA-MATCHED, UNRELATED STEM CELL
TRANSPLANTS
Warden, M.B.1, Haagenson, M.2,3, Wang, T.2,3, Pietz, B.C.1,
Goulmy, E.4, Warren, E.H.5, Spellman, S.2,3, Ellis, T.M.1 1Bloodcenter
of Wisconsin, Milwaukee, WI; 2Center for International Blood and
Marrow Transplant Research, Milwaukee, WI; 3National Marrow Do-
nor Program, Minneapolis, MN; 4Leiden University, Leiden, Nether-
lands; 5Fred Hutchinson Cancer Research Center, Seattle, WA.
This study assessed the effect of single and multiple minor
histocompatibility antigen (mHAg) mismatches on outcomes of
730 unrelated donor, HLA-A, B, C, DRB1 and DQB1 allele-
matched transplants facilitated by the National Marrow Donor
Program (NMDP) between 1996 and 2003. The study popula-
tion included patients with acute and chronic leukemia and
myelodysplastic syndrome. Bone marrow was the predominant
source of hematopoietic cells (85%). All patients received my-
eloablative conditioning regimens and calcineurin inhibitor-
based graft-versus-host-disease (GvHD) prophylaxis. The me-
dian follow-up was 5 years (range: 0.9-8.9). DNA samples from
both donor and recipient were obtained from the NMDP Re-
search Sample Repository and genotyped for mHAg including:
HA-1, HA-2, HA-3, HA-8, HB-1, and CD31. Patients carrying
multiple relevant HLA alleles were evaluated for the impact of
multiple mHAg mismatches. Numbers of recipient/donor pairs
mismatched for each mHAg and power to detect a difference in
survival rates are indicated in Table 1. Primary outcomes in-
cluded grades II-IV acute GvHD and survival; secondary out-
comes tested included chronic GvHD, engraftment, and relapse.
Single disparities at HA-1, HA-2, HA-3, HA-8, HB-1 and
CD31 were not signiﬁcantly associated with any of the out-
comes analyzed. Signiﬁcant associations with transplant out-
comes were observed only when disparities existed at multiple
mHAg loci. Signiﬁcantly lower survival was observed for indi-
viduals mismatched for both CD31 and HA-3 in the GvH
direction versus those matched (RR2.01, 95% CI(1.14-3.55,
p0.017) or mismatched at a single locus for these mHAg
(RR2.38, 95% CI(1.32-4.35), p0.0043). In addition, pairs
mismatched at both CD31 and HA-3 in the GvH direction
exhibited higher transplant related mortality (TRM) than pairs
mismatched at a single locus (RR2.50, 95% CI(1.27-4.76),
p0.009). The results for single mHAg mismatches at HA-1,
HA-2, HA-3, HA-8, HB-1 and CD31 show no evidence of an
effect on outcomes, but the power is limited by the population
size (Table 1). However, multiple mHAg mismatches are asso-
ciated with signiﬁcantly lower survival and increased TRM
when considering HA-3 and CD31 under the HLA-A*01 re-
striction.
Table 1. Study Summary
mHAg
HLA
Restriction
mHAg
Matched
Pairs
mHAg
Mismatched
Pairs
p-Value
(Log rank
test)
Power to
Detect
Difference
in
Survival
HA-1 A*02
(N430)
228 202 0.25 85%
HA-2 A*02
(N430)
397 33 0.55 6%
HA-3 A*01
(N327)
249 78 0.054 45%
HA-8 A*02
(N-430)
269 161 0.94 5%
HB-1 A*44
(N257)
129 128 0.79 6%
CD31 Unknown 286 444 0.30 17%
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CHANGES IN TNFR1 RATIOS IN THE FIRST WEEK POST-MYELOABLA-
TIVE ALLOGENEIC BMT CORRELATE WITH GVHD, TRM AND OS IN
CHILDREN
Kitko, C.1, Paczesny, S.1, Yanik, G.1, Braun, T.1, Jones, D.1,
Whitﬁeld, J.1, Choi, S.1, Hutchinson, R.1, Ferrara, J.1, Levine, J.E.1
1Blood and Marrow Transplantation Program, University of Michigan,
Ann Arbor, MI.
Graft-vs-host disease (GVHD) remains the major cause of
morbidity and treatment-related mortality (TRM) after alloge-
neic hematopoietic stem cell transplantation (HSCT). Pre-clin-
ical studies show that inﬂammatory cytokines such as tumor
necrosis factor- (TNF) are signiﬁcant in the pathogenesis of
GVHD. We tested the hypothesis that early rises in TNF (on
day 7 following allogeneic HSCT) predict the development of
signiﬁcant GVHD and TRM. TNF circulates as a complex
bound to its receptors. We therefore measured soluble TNF
receptor 1 (TNFR1) levels pre-HSCT and on day 7 post-HSCT
as a surrogate marker for TNF in 82 children (median age 8.8y,
range 0.8-17.8y) who underwent myeloablative HSCT.
Preparative regimens included Busulfan (71%), BCNU (17%),
and TBI (12%). There were 38 related donor recipients (46%),
38 unrelated donor recipients (46%) and 6 cord blood recipients
(8%). GVHD median day of onset was 20d, almost two weeks
after TNFR1 levels were measured.
Because of the variability in baseline TNFR1 levels, we ex-
pressed the day 7 value as a ratio to pretransplant baseline. The
mean day 7 TNFR1 ratio correlated with severity of GVHD.
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The mean day 7 TNFR1 ratio was 1.7 for patients with GVHD
0-1 (n50), 2.6 for patients with GVHD 2 (n19), and 3.1 for
patients with GVHD 3-4 (n13), p0.01.
We tested whether subjects whose day 7 TNFR1 ratio was in
the top quartile (day 7 TNFR1 ratio  2.5) were at increased
risk of developing GVHD 2-4, 1y TRM, and 1y survival com-
pared to subjects whose day 7 TNFR1 ratio was below the 75th
percentile. Subjects with day 7 TNFR1 ratios above 2.5 were
almost twice as likely to develop GVHD 2-4 and had an almost
50% increase in probability of death by 1 year. Because age is an
independent risk factor for GVHD, these results were compared
to a larger cohort of 355 adult patients (medain age 46.5y, range
18.3-65.2y) and a statistically signiﬁcant correlation between
TNFR1 day 7 ratios and GVHD 2-4, TRM and survival was
also observed [Table 1]. In additional analyses, TNFR1 day 7
ratios were an important predictor independent of donor
source.
We conclude that for children undergoing HSCT, the mag-
nitude of rise in TNFR1 after myeloablative transplant corre-
lates with the subsequent development of GVHD, TRM and
survival. These informative changes are detectable on day 7, up
to two weeks in advance of clinical manifestations of GVHD,
and may therefore be useful in developing of a predictive labo-
ratory test.
Table 1
TNFR1 Ratio
GVHD
2-4
1 YR
TRM
1 YR
Survival
Children (n82) Median age 8.8y (range 0.8-17.8y)
TNFR1 < 2.5 (n63) 33% 6% 77%
TNFR1 > 2.5 (n19) 58% 26% 53%
p0.02 p0.07 p0.04
Adults (n355) Median age 46.5y (range 18.3-65.2y)
TNFR1 < 2.5 (n264) 31% 19% 62%
TNFR1 > 2.5 (n91) 60% 41% 48%
p<0.001 p<0.001 p0.02
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POST-TRANSPLANTATION HIGH-DOSE CYCLOPHOSPHAMIDE (CY) IS EF-
FECTIVE SINGLE AGENT GVHD PROPHYLAXIS THAT PERMITS PROMPT
IMMUNE RECONSTITUTION AFTER MYELOABLATIVE HLA MATCHED RE-
LATED AND UNRELATED BONE MARROW TRANSPLANTATION (BMT)
Luznik, L.1, Fuchs, E.J.1, Chen, A.R.1, Kaup, M.1, Bright, E.C.1,
Bolanos-Meade, J.1, Hess, A.D.1, Jones, R.J.1 1Divsion of Hematologic
Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns
Hopkins, Baltimore, MD.
Prolonged pharmacologic immunosuppression is a major obstacle
to early immunologic recovery after allogeneic BMT. Based on our
results in animal models, we studied whether high dose Cy alone after
HLA-matched related or unrelated BMT is effective prophylaxis
against severe acute GVHD while permitting effective reconstitution
of lymphocytes, including regulatory T cells (Tregs). Forty-six consec-
utive patients (median age 41, range 1-64) with advanced hematologic
malignancies received HLA-matched related (n28) or unrelated
(n18) bonemarrow after conditioning with busulfan on days -7 to -3
and Cy (50 mg/kg/day) on days -2 and -1,3, and4. No additional
GVHD prophylaxis was administered. The cumulative incidence of
acute grades II-IV and grades III-IV GVHD were 41% and 9%,
respectively. Of the thirty-six patients alive after day 100, only 1 of the
23 patients that received HLA-matched related, and 3 of 13 patients
that received unrelated allografts, developed chronic GVHD. With a
median of 13 months (range 8-26 months) of follow-up, 26 (56%)
patients are alive, of whom 21 (45%) are in complete remission.
PBMCs collected at day 30-40, 40-60 and 60 post-transplant were
evaluated enumerating CD4Foxp3 cells by multi-color ﬂow-cy-
tometry and quantifying Foxp3, INF-, IL-2 and IL-10 mRNA tran-
scripts by quantitative PCR. Patients with grade II-IV acute GVHD
had signiﬁcantly fewer CD4Foxp3 T cells compared to patients
with grade 0-I GVHD (p0.05). Development of grade II-IV
GVHD negatively correlated with the expression of the Foxp3
(p0.05) and was associated with marginally higher expression of
INF- mRNA (p0.08) suggesting higher effector function in the
absence of Tregs in patients with grade II-IV GVHD. Expression of
IL-2 mRNA transcripts was signiﬁcantly higher in patients with grade
II-IVGVHD compared to patients with grade 0-I GVHD (p0.001).
Differences in IL-10 mRNA expression was not observed. These
results suggest that high-dose of post-transplantation Cy is effective as
a single agent for prevention of GVHD after HLA-matched related
or unrelated BMT. The rapid recovery of Tregs associated with this
strategy may also be responsible for the unexpectedly low incidence of
chronic GVHD; however, longer follow-up and larger numbers of
patients are needed.
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